Filter your search
Kalorama Information is the authoritative market research source for the diagnostics industry. Find essential insights, market shares, sales segmentation and projections for in vitro diagnostics (IVD) and medical imaging markets. Kalorama’s reports, including The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 13th edition, analyze the global in vitro diagnostics market, now worth approximately $83.3 billion. Our diagnostics market research covers trends in health care service delivery, including the rapidly advancing diagnostic laboratory technology industry. Discover emerging diagnostics market niches in our updated reports that present the trends, technologies, customer needs, and major suppliers currently shaping the diagnostics industry.
Molecular Assays
Point-of-Care
Immunoassays
Infectious Disease
Clinical Chemistry
Oncology/Hematology
Lab Testing Services
Medical Imaging
- $1,496.00 – $2,992.00Diagnostic testing for prion diseases has become more important as countries increase the number of tests to battle the potential public health problem. Academic, government, and industry organizations continue to develop diagnostic testing technologies and policies as preventative measures. The number of prion diagnostic technologies being used and developed for prion diseases primarily reflects the […]October 1, 2003$2,625.00 – $5,250.00Genetic testing is already in widespread use and will continue to grow in many application areas in the next five years. The number of companies offering genetic testing services and/or commercial genetic testing products continues to grow around the world. There are at least 50 companies offering genetic testing services or commercial products for a […]May 1, 2003$596.00 – $1,192.00To succeed in the diagnostics market of the 21st Century, a company has to have either a strong niche position in a particular market segment or be a jack of all trades. In either case, a full or comprehensive menu is critical. Why reinvent the wheel? Most tests and systems are already available somewhere, offered […]February 1, 2003